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microRNAs (miRNAs) are a class of non-coding RNAs that function as endogenous triggers of the RNA 
interference pathway. Studies have shown that thousands of human protein-coding genes are regulated by 
miRNAs, indicating that miRNAs are master regulators of many important biological processes, such as cancer 
development. miRNAs frequently have deregulated expression in many types of human cancers, and play 
critical roles in tumorigenesis, which functions either as tumor suppressors or as oncogenes. Recent studies 
have shown that miRNAs are highly related with cancer progression, including initiating, growth, apoptosis, 
invasion, and metastasis. Furthermore, miRNAs are shown to be responsible for the cancer-related inflam- 
mation, anti-cancer drug resistance, and regulation of cancer stem cells. Therefore, miRNAs have generated 
great interest as a novel strategy in cancer diagnosis and therapy. Here we review the versatile roles of miRNAs 
in cancers and their potential applications for diagnosis, prognosis, and treatment as biomarkers. 
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  microRNAs (miRNAs), which negatively regulate gene 
expression at the post-transcriptional and/or translational 
level, are short non-coding RNAs 19–25 nucleotides in 
length, first discovered in Caenorhabditis elegans to 
control developmental timing [1-3]. Mature miRNAs are 
formed from longer primary transcripts by two se- 
quential processing steps mediated by a nuclear (Drosha) 
and a cytoplasmic (Dicer) RNase ċ endonulease [4-5]. 
In most animals, miRNAs direct gene regulation at the 
level of translation. They can down-regulate gene expre- 
ssion either by degradation of messenger RNA (mRNA) 
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through the RNA interference (RNAi) pathway or by 
inhibiting protein translation [6]. To date, over 1 000 
miRNAs have been identified in animal genomes through 
cloning and bioinformatics approaches. Although the bio- 
logical roles of only a small fraction of identified miRNAs 
have been elucidated, in mammals, these miRNAs regulate 
processes essential to cell growth, embryogenesis, stem 
cell maintenance, hematopoietic cell differentiation, and 
brain development [7-11]. Since Croce’s research group 
first reported the link between the abnormal expression 
of miRNAs and cancer in 2002 [12], more and more 
studies have shown that many miRNAs take part in the 
progressions of various cancers, including tumor growth, 
differentiation, adhesion, apoptosis, invasion, and metas- 
tasis [13-15]. Cancer is ultimately a consequence of 
disordered gene expression. miRNA profiling experiments 
have revealed that many miRNAs are abnormally 
expressed in clinical cancer samples. In addition, in in 
vitro and in vivo models, these abnormal expressions 
have been pointed out to be closely related to various 
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biological behaviors of cancers [16-17]. Thus, alterations 
of miRNAs expression may promote tumor formation by 
modulating the functional expression of critical genes 
involved in tumor development and progression [18]. 
Here we present the progress of miRNAs in cancers and 
prospect the great potential of miRNAs in cancer diag- 




miRNAs were reported to be involved in tumorige- 
nesis by targeting tumor suppressor genes or oncogenes 
directly or indirectly. Because miRNAs are negative re- 
gulators of gene expression, the changes of the expre- 
ssion level of these miRNAs can be tumorigenic if they 
target mRNAs from a tumor suppressor gene, as well as 
an oncogene. For example, miR-373 was identified as an 
oncogene that cooperates with Ras in oncogenic trans- 
formation by a suppressing signaling through the p53 
pathways [19]; miR-31 was found to directly target tumor 
suppressor genes, large tumor suppressor 2 (LATS2) and 
protein phosphatase 2A (PP2A) regulatory subunit B 
alpha isoform, and repress lung cancer cell growth and 
tumorigenicity independently and substantially [20]; 
miR-183, as an oncogene by targeting early growth 
response 1 (EGR1) and phosphatase and tensin homolog 
(PTEN), was significantly overexpressed in synovial 
sarcoma, rhabdomyosarcoma, and colon cancer cell lines, 
and promoting the tumor cell migration [21]; miR-93, 
one of the miRNAs within the miR-106b-25 cluster, was 
able to promote tumor growth and angiogenesis by 
targeting integrin-β8 which was associated with cell death 
in tumor mass in vivo [22]; Another well-characterized 
example is the miR-17-92 cluster which is transcrip- 
tionally activated by the oncogene c-Myc. They are 
susceptibility gene at the chr13q13 amplicon and reported 
to have the causal role in cancer. In a mouse model for 
lymphoma, co-expression of miR-17-19b, a truncated 
portion of miR-17-92, strongly accelerated lymphoma- 
genesis [23]; miR-17-5p and miR-20a, two of the 
miRNAs in the miR-17-92 cluster, could repress the 
translation of E2F1, a protein that is increased by c-Myc 
and enhance both cell cycle progression and apoptosis 
[24-25]. Medina et al. [26] showed that overexpression 
of miR-21 led to a pre-B malignant lymphoid-like 
phenotype in vivo. When miR-21 was inactivated, the 
tumors regressed completely in a few days, partly as a 
result of apoptosis. Their results supported efforts to 
treat human cancers through pharmacological inacti- 
vation of miRNAs such as miR-21. This conclusion was 
also confirmed in breast cancer, colon cancer, pancreas 
cancer, lung cancer, prostate cancer, liver cancer, stomach 
cancer, and oral squamous cell carcinoma (OSCC) [27- 
32]. Evidence above showed that these tiny non-coding 
RNAs were playing important roles in the malignant 




miRNAs have been implicated as tumor suppressor 
genes. Typical examples are miR-15a and miR-16, which 
are down-regulated in 68% of chronic lymphocytic leu- 
kemia (CLL). Since these two miRNAs can negatively 
regulate the expression of the anti-apoptotic factor BCL2, 
their down-regulation could result in higher BCL2 protein 
level and anti-apoptotic activity [33-34]. Let-7/miR-98 
family is another example for down-regulation of 
miRNAs that target a number of well-known onco- 
genes. The roles of let-7 and miR-98 as suppressors in 
lung cancer were supported by experiments showing that 
they negatively regulate the expression of the Ras and 
Myc oncogenes [35-36]. miR-330 was reported to have 
the suppression roles by negatively regulating E2F1 and 
inducing apoptosis through E2F1-mediated suppression 
of Akt phosphorylation in human prostate cancer cell 
lines PC-3 [37]. A similar situation was also applied to 
miR-34a, which was reported to directly target E2F3 and 
significantly reduced the level of E2F3 protein (a protein 
transcriptional inducer of cell-cycle progression), acting 
as a potential tumor suppressor by inducing apoptosis. 
miR-34a also participated in the regulation of tumor cell 
scattering, migration, and invasion via down-regulation 
of c-Met and its downstream signaling cascades [38]. In 
general, the genomic alterations, particularly tumor 
suppressor genes amplification or oncogene deletion, 
can be a major mechanism of inactivation of the tumor 
suppression function of miRNAs.  
Interestingly, recent estimates suggested that as many as 
50% of all nucleotides were transcribed and only 2% of 
nucleotides reside in known exons. Moreover, more than 
half of such transcripts are non-polyadenylated. These 
RNAs would be invisible to many analyses because the 
first step is often reverse transcription from the “canonical” 
polyA tail. And miRNAs are one major group of these 
hidden RNAs. It is remarkable, because these findings 
raise the possibility that many miRNAs as oncogenes or 
suppressors remain to be discovered [39-40]. 
 
Invasion and metastasis 
 
Invasion and metastasis are responsible for >90% of 
cancer-related mortality. As tumors progress with increa- 
sed malignancy, cells within them develop the ability to 
invade into surrounding normal tissues and through 
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tissue boundaries to form new growths (metastases) at 
sites distinct from the primary tumor. The molecular 
mechanisms involved in this process are associated with 
cell-cell and cell-matrix adhesion, with the degradation 
of extracellular matrix, and with the initiation and main- 
tenance of early growth at the new site [41-42]. 
Epithelial-mesenchymal transition (EMT), mainly cha- 
racterized by E-cadherin degradation, is an important 
event in invasion and metastasis. E-cadherin, which is 
encoded by E-cadherin gene (CDH1) and regulated by 
Snail, Slug, Zeb1, Zeb2, Klf8, Twist1 and Twist2, is a 
well-known molecule witch maintains the cell-to-cell 
junctions in epithelial cells [43-44]. Its aberrant expre- 
ssion has been implicated in cancer progression and 
metastasis [45-46]. miR-373 was considered to have an 
effective role in E-cadherin targeting. It has been 
confirmed that the transfection of miR-373 and its 
precursor hairpin RNA into PC-3 cells readily induced 
E-cadherin expression. Together with miR-520c, they are 
considered to be metastasis-promoting miRNAs by direct 
suppression of CD44 which is consistently reduced in 
metastatic breast, colon and prostate cancers [47-50]. 
In breast cancer cells, both miR-10b and -9 are impor- 
tant participants of invasion and metastasis. Homeobox 
D10 (HOXD10) is a validated target of miR-10b. Ectopic 
expression of miR-10b has consistently led to the down- 
regulation of HOXD10 expression, and in turn, the 
induction of RhoC expression. Importantly, either over- 
expression of HOXD10 or knockdown of RhoC almost 
completely reversed miR-10b-induced migration and 
invasion in vitro [51]. It has been shown that miR-9 
could directly target CDH1, the E-cadherin encoding 
mRNA, leading to increased cell motility and invasive- 
ness [52]. miR-21 was found up-regulated in many solid 
tumors. When anti-sense oligo against miR-21 was 
introduced into metastatic cancer cells, their metastatic 
ability was inhibited, as gauged by a tail-vein metastasis 
assay and a chick-embryo chorioallantoic-membrane 
metastasis assay. With further study, it was found that 
miR-21 could target phosphatase and tensin homolog 
(PTEN), tumor suppressor gene tropomyosin 1 (TPM1), 
and programmed cell death 4 (PDCD4), to promote the 
metastasis of cancers [53-57]. Meanwhile, some miRNAs 
play a role in inhibiting tumor invasion and metastasis. 
The let-7 miRNA family of tumor suppressors is down- 
regulated in a variety of tumors. This family of miRNAs 
has been identified as the silencer of the Ras and 
HMGA2 oncogenes which promote tumor metastasis 
[36, 58-60]. The miR-200 family, organized as two 
clusters in the genome, were expressed during EMT and 
able to hinder EMT by enhancing E-cadherin trans- 
criptional expression through directly targeting Zeb1 and 
Zeb2 [61-63]. Martello have shown that high levels of 
miR-103/-107 were associated with metastasis and poor 
outcome in human breast cancer. At the cellular level, a 
key event fostered by miR-103/-107 was the induction 
of EMT, attained by down-regulating miR-200 levels 
[64]. Hedgehog signaling cascade cross-talks with Wnt, 
epidermal growth factor (EGF)/fibroblast growth factor 
(FGF), and tumor growth factor-β (TGF-β/Activin/Nodal/ 
bone morphogenetic protein (BMP) signaling cascades, 
which are implicated in epithelial-mesenchymal transition 
(EMT) through E-cadherin repression [65-67]. It was 
reported that TGF-β could down-regulate the expre- 
ssion of human miR-141, -200a/b/c, -205, and -429, which 
in turn down-regulate Zeb1 and Zeb2. It is noteworthy 
that these miRNAs may play important roles in EMT as 
participants in the Hedgehog signaling cascade [68]. 
Angiogenesis is another important mechanism in 
cancer invasion and metastasis. It frequently happens in 
various tumors and is highly related with invasion, 
metastasis and poor outcome [69]. Early studies have 
indicated the contribution of specific miRNAs (e.g. 
miR-21, -155, and 126) to vascular diseases [70]. At 
present, miR-126 is widely accepted as an important 
factor for angiogenesis. Two groups published their 
investigations back-to-back that miR-126 could regulate 
the response of endothelial cells to vascular endothelial 
growth factor (VEGF), and regulate vascular integrity and 
angiogenesis in vivo [71-72]. Nicoli et al. [73] reported 
that zinc finger transcription factor Klf2a induced the 
expression of miR-126 leading to the activation of the 
VEGF signaling pathway. Their work described a novel 
genetic mechanism in which a miRNA facilitated the 
integration of a physiological stimulus with growth factor 
signaling in endothelial cells to guide angiogenesis. Epi- 
dermal growth factor-like domain 7 (EGFL7) was des- 
cribed as a novel endothelial cell-derived factor involved 
in the blood vessel formation. Fish and colleagues 
described the transcriptional regulation of EGFL7 in 
human endothelial cells by miR-126 [71]. Sun et al. [74] 
reported that EGFL7 was a direct target of miR-126 in 
lung cancer cells and hinted that this could be at least 
partly explain the observed effect of miR-126 on tumori- 
genesis. Taken together, these results demonstrated that 
miR-126 and EGFL7 may share a tightly regulated 
function in tumor vessel formation. Except the miRNAs 
mentioned above, miR-17/-20, -31, and -335 have all 
been shown to have inhibitory roles in tumor invasion 
and metastasis as demonstrated in recent studies [75-76].          
 
miRNAs and cancer-related inflammation 
 
Chronic inflammation is a major cause of cancer. 
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Epidemiologic and clinical studies show that appro- 
ximately 25% of all human cancers in adults result from 
chronic inflammation. The oncogenic mechanisms in 
chronic inflammation are complicated and not fully 
revealed. Some studies have suggested that induced epi- 
genetic changes and genomic instability were involved 
in inflammation-induced carcinogenesis. Several trans- 
cription factors and key inflammation mediators, such as 
tumor necrosis factor-α (TNF-α), cyclooxygenase-2 
(COX-2), cytokines, hypoxia inducible factor-1α (HIF-1α), 
and nuclear factor-κB (NF-κB), have been identified as 
playing important roles inflammation-induced cancers 
[77-79]. miRNAs have emerged as a critical regulatory 
factor in the mammalian immune system. Genetic abla- 
tion of the miRNA machinery, as well as loss or 
deregulation of certain individual miRNAs, severely 
compromises immune response leading to immune 
disorders like autoimmunity and cancer [80].  
miR-146a is one of the first miRNAs identified to be 
involved in the regulation of immune function. Lipo- 
polysaccharide (LPS)-induced induction of miR-146a 
was observed in several other cell lines of myeloid 
origin, but not in B cell lines, suggesting the LPS- 
induced regulation of miR-146a is cell-type specific. In 
addition to the effect on Toll-like receptor (TLR) ligands, 
miR-146a was induced by TNF-α and interleukin (IL)- 
1β in an NF-κB dependent manner [81-82]. miR-21 is 
one of the most abundant miRNAs in T cells in the 
immune system, indicating that it is critical for T cell 
homeostasis [83]. In the expression profiling studies 
during the innate immune response to aerosolized LPS 
in the mouse lung, miR-21 was found to be involved in 
the inflammatory responses [84]. Recent research has 
shown that miR-21, expressed by inflammatory leuko- 
cytes, was the most highly induced miRNA in an 
IL-13-induced asthma mode. One potential target for 
miR-21 is IL-12p35, a subunit of IL-12, a key cytokine 
from macrophages and dendritic cells involved in 
adaptive immune responses [85]. Schetter et al. [86] 
examined the expression of 23 inflammatory genes in 
colon adenocarcinomas and adjacent noncancerous tissues 
from 196 patients. The results showed that miR-21 was 
functionally associated with IL-6, -8, -10, -12a and nitric 
oxide synthase 2a (NOS2a), suggesting that miR-21 
expression was associated with cancer-specific mortality 
and cancer-related inflammation. These results imply 
that miR-21 might contribute to the inflammation- 
induced cancers, at least part, by modulating cytokine 
responses. miR-155 is regarded as a multifunctional 
miRNA. Besides acting as an important oncogene, it 
plays essential roles in both B and T cell response 
identified by two independent groups [87-89]. Similar to 
miR-146, miR-155 is regulated by LPS in mouse 
macrophages. It is also regulated by virally relevant 
stimuli, such as the synthetic TLR3 ligand poly and by 
antiviral response cytokines (interferin (IFN)-β, -γ), 
suggesting that miR-155 is a component of the innate 
immune response [81, 90-91]. Overexpression of miR- 
155 also caused the repression of tumor through targeting 
p53-induced nuclear protein 1, a pro-apoptotic gene 
downstream of p53 signaling, suggesting that miR-155 
has a pro-tumorigenic function via regulation of inflam- 
mation-induced carcinogenesis [92].  
miR-17-92 cluster encodes six miRNAs (miR-17, 
-18a, -19a, -19b-1, -20a, and -92-1) in the human 
genome. Studies on mouse models have implicated the 
importance of miR-17-92 cluster in B cell development 
and T cell function. In addition, in vivo studies indicate a 
role for these miRNAs in monocytic development [93-95]. 
These findings suggest that there might be a potential 
link between the expression of miR-17-92 cluster and 
immune system. However, the exact roles of miR-17-92 
in inflammation need further investigations. Iliopoulos et 
al. [96] found that let-7 directly inhibited IL6 expression, 
resulting in higher levels of IL6 than achieved by NF-κB 
activation in several cancer cell lines. This result suggests 
that let-7 might be important to the cancer-related 
inflammation. Except the miRNAs described above, 
many other miRNAs, such as miR-9, miR-101, -192, 
and -203, have been also associated with inflammatory 
diseases or immune responses [97-102].  
 
miRNAs and cancer stem cells  
 
Cancer stem cell (CSC) model in tumorigenesis pro- 
poses that a small fraction of cells in a tumor has pro- 
perties of stem cells, being responsible for initiating and 
maintaining the tumor. miRNAs have been found specially 
expressing in CSCs and controlling their self-renewal 
and differentiation through regulating the expression of 
certain key genes [103-106]. Yu et al. [107] found that 
let-7 regulated multiple stem cell-like properties of breast 
tumor-initiating cells (BT-ICs) by silencing Harvey rat 
sarcoma virus oncogene or high mobility group AT- 
hook 2 (HMGA2). Another study showed that enforced 
let-7 expression depleted the self-renewing compartment 
through identification of miRNA signature in a popu- 
lation of purified self-renewing progenitor cells [108]. 
miR-205 and -22 were found to highly express in 
mammary progenitor cells, while let-7 and miR-93 were 
depleted. Further studies demonstrated that let-7 sensors 
could be used to prospectively enrich self-renewing 
populations, and that enforced let-7 expression induced 
loss of self-renewing cells from mixed cultures. These 
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results revealed a role for let-7 in regulating stemness, 
suggesting that miRNAs might play important roles in 
CSC proliferation, differentiation and tumor formation. 
Some miRNAs themselves are considered to be stem 
cell-like miRNAs recently. Cairo et al. [109] reported 
that undifferentiated aggressive hepatoblastoma (HBs) 
overexpressed the miR-371-3 cluster with concomitant 
down-regulation of the miR-100/let-7a-2/miR-125b-1 
cluster. Their combined deregulation cooperated in modu- 
lating the hepatic tumor phenotype, implicating stem 
cell-like regulation of Myc-dependent miRNAs in poorly 
differentiated HBs. This important finding adds miRNAs 
as new role in tumor regulation. 
 
miRNAs and anticancer drug resistance  
 
Drug resistance remains a major clinical obstacle to 
successful treatment. The understanding of the drug 
resistance mechanism is important for the cancer therapy. 
Increasing evidence has indicated that aberrant miRNA 
expression is strongly implicated in anticancer drug 
resistance [110-112]. Significant overexpression of 8 
miRNAs and down-regulation of 7 miRNAs were detec- 
ted in a tamoxifen-resistant breast cancer cell line com- 
pared with the tamoxifen-sensitive cell line [113]. 
Kovalchuk et al. [114] reported that miR-451 regulated 
the expression of multidrug resistance 1 (MDR-1) gene 
in the doxorubicin-resistant human breast adenocarci- 
noma cell line MCF-7. In ovarian cancer, Yang et al. 
[115] demonstrated that the up-regulation of miR-214 
promoted the survival of ovarian cancer cells and 
induced resistance of cisplatin. Sorrentino et al. [116] 
showed that a panel of miRNAs (let-7e, miR-30c, -125b, 
-130a and -335) were diversely expressed in all the 
resistant cell lines of ovarian cancer. In non-small cell 
lung cancer, 5 miRNAs (miR-15b, -100, -125b, -221, 
and -222) were found to up-regulate in the resistant cell 
lines [117]. Forced overexpression of the miR-222, -100, 
and -221 in the sensitive H460 cells increased resistance 
to TNF-related apoptosis inducing ligand (TRAIL), 
indicating that inhibition of their target proteins results 
in TRAIL resistance. Bertino et al. [118] put forward the 
concept of miRNA pharmacogenomics, a novel and 
promising field of research that holds new possibilities 
for medical therapy. This model can be defined as the 
study miRNAs and the miRSNPs/polymorphisms in 
their target genes may determine drug behavior in order 
to improve efficiency of drugs. Upon reaching a deeper 
understanding of the mechanism of miRNA in anticancer 
drug resistance, miRNAs might well fulfill their promise 
as valuable therapeutics in overcoming anticancer drug 
resistance. 
miRNAs related cancer diagnosis and therapy 
 
As the important roles of miRNAs in cancer are 
gradually revealed, their potential applications as useful 
and effective targets have generated great interest in 
cancer gene therapy strategies, as well as diagnosis, 
classification, prognosis and risk factor evaluations. 
Based on microarrays for miRNA expression profiling 
studies, differences in miRNA expression could be 
detected between normal and cancer tissues, which can 
classify different tumor types and tumor grades [119- 
121]. Certain miRNA signatures are correlated with 
prognosis and can potentially be used to determine the 
specific course of treatment. Michael et al. [122] found 
aberrant miRNA expression in solid tumors as they 
identified 28 different miRNAs in colonic adenocar- 
cinoma compared with normal mucosa. miR-143 and 
-145 were significantly down-regulated in the cancer. 
Similar situation was detected in other cancers, as 
miR-221, -222, and -146 in papillary thyroid carcinoma 
[123], miR-21 and -155 in pancreatic cancer [124], and 
miR-141 in prostate cancer [125]. Through analyzing the 
expression of 217 miRNAs in 334 samples that included 
primary tumors, tumor-derived cell lines and normal 
tissues, Lu et al. [16] found that miRNA profiles can 
distinguish between normal and cancer tissues, separate 
different cancer types, stratify the cancer differentiation 
state and cluster sample groups according to their emb- 
ryonic lineage. Single nucleotide polymorphisms (SNPs) 
within the miRNA coding genes or within miRNA target 
genes are likely to be deleterious and can affect an 
individual’s risk to develop diseases such as cancers. Yu 
et al. [126] found that 12 miRNA-related SNPs showed 
an aberrant allele frequency in human cancers. Chin et al. 
[127] identified an SNP in let-7 complementary site 6 
(LCS6) in the KRAS 30 UTR that is associated with 
smoking-induced lung cancer risk. This variant allele is 
found in 20% of the 74 non-small cell lung carcinoma 
patients in the study. These unique miRNA expression 
signatures might be the hallmarks of tumor progressions 
and prognosis evaluations.  
Many miRNAs, as discussed above, have great poten- 
tial in tumorigenesis, tumor invasion, ametastasis, malig- 
nant progression, and poor prognosis. In in vitro and in 
vivo experiments, it has been confirmed that knockdown 
of certain miRNAs could change the tumor progression 
and biological characteristics as potential therapeutic 
targets [128-129]. In cell culture and xenograft mice 
models, synthetic anti-miRNA oligonucleotide (AMO) 
with 2’-O-methyl modification have been shown to 
effectively inhibit endogenous miRNAs. Krützfeldt et al. 
[130] studied the utility of AMOs in vivo through 
microRNAs in cancers 
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intravenous injection of modified AMOs to target the 
liver-specific miR-122. Impressively, a single injection 
of 240 mg· kg-1 body weight conferred specific miR-122 
silencing for up to 23 days. As an alternative to 
2ʹ-hydroxyl-modified AMOs, lock nucleic acid based 
oligonucleotides (LNA-antimiR) have been shown to be 
more stable and less toxic in inhibiting endogenous 
miRNAs in vivo. Kota et al. [131] showed that the 
systemic delivery of a single miRNA could cause tumor 
regression in a mice model of liver cancer. They 
delivered adeno-associated virus 8 (AAV8)-expressing 
miR-26a intravenously in Myc-induced mice harboring 
preformed liver tumors. After 3 weeks, they observed a 
significant regression of tumors in mice with the 
miR-26a treatment. These findings indicate a possibility 
of specific miRNAs-target therapy. 
 
Conclusion and perspective 
 
The importance of miRNAs in cancer has been well 
established and some special miRNAs have been regarded 
as hallmarks in tumor progressions and hot targets in 
cancer therapy. However, there is still a long and arduous 
way to go for substantial applications of miRNAs in 
cancer treatments. To date, the exact mechanisms and 
entire networks of miRNAs in cancer progressions are 
still unclear, and there is even some controversy about 
their roles in tumor regulation. For example, Ma et al. 
[52] reported that miR-9 acted as an oncogene and 
regulates the metastasis of lung cancer cell, while Wan et 
al. [132] suggested miR-9 as a tumor suppressive gene 
by targeting NF-κB in gastric cancer; Similarly to miR-9, 
-107 and -125b function as oncogenes in some tumors 
and as a tumor-suppressor in others [133-138]. In OSCC, 
expression of miR-31 was reported to be up-regulated 
[139-140]. However, it appeared to down-regulation in 
gastric carcinoma and prostate carcinoma [141-142]. 
These results need to be further confirmed. It is also 
possible that the contradictory results implied regulation 
mechanisms uncovered in the relationships between 
miRNAs and cancers. One hypothesis is that certain 
miRNAs might have different roles in different tissues or 
different cancer types, or even there are some unknown 
molecules or genes regulating the same miRNAs to 
perform various roles in different situations. As a “star 
molecule” since 2002, miRNAs have become the focus 
in recent years and the studies of their roles in cancers 
have continued. In 2010, Guo et al. [143] found that 
changes in mRNA levels closely reflected the impact of 
miRNAs on gene expression, indicating that destabili- 
zation of target mRNAs was the predominant reason for 
reduced protein output. This means that miRNAs play 
their roles mainly by degrading the target mRNA (≥84% 
lowered mRNA levels account for of the decreased 
protein production) rather than by inhibiting their 
translation. Meanwhile, Zhang et al. [144] reported that 
cells can secrete miRNAs and deliver them into recipient 
cells where the exogenous miRNAs can regulate target 
gene expression and recipient cell function as signaling 
molecules mediating intercellular communication. These 
results provide the potential mechanism of miRNAs in 
cancers, and indicate a novel approach for future 
research. Although our knowledge about the exact roles 
of miRNAs as well as their regulating genes in cancers 
is limited, we believe that the prospects of cancer 
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